Beam Therapeutics Inc (BEAM)
24.73
+0.94
(+3.95%)
USD |
NASDAQ |
May 17, 16:00
24.73
0.00 (0.00%)
After-Hours: 20:00
Beam Therapeutics Research and Development Expense (Quarterly): 84.82M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 84.82M |
| December 31, 2023 | 140.08M |
| September 30, 2023 | 100.05M |
| June 30, 2023 | 97.61M |
| March 31, 2023 | 99.65M |
| December 31, 2022 | 86.34M |
| September 30, 2022 | 85.29M |
| June 30, 2022 | 74.56M |
| March 31, 2022 | 65.41M |
| December 31, 2021 | 96.78M |
| September 30, 2021 | 54.62M |
| June 30, 2021 | 45.58M |
| Date | Value |
|---|---|
| March 31, 2021 | 190.11M |
| December 31, 2020 | 32.45M |
| September 30, 2020 | 29.82M |
| June 30, 2020 | 19.35M |
| March 31, 2020 | 21.55M |
| December 31, 2019 | 20.22M |
| September 30, 2019 | 12.54M |
| June 30, 2019 | 12.68M |
| March 31, 2019 | 9.179M |
| December 31, 2018 | 9.852M |
| September 30, 2018 | 9.854M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
12.54M
Minimum
Sep 2019
190.11M
Maximum
Mar 2021
68.48M
Average
69.98M
Median
Research and Development Expense (Quarterly) Benchmarks
| Eli Lilly and Co | 2.523B |
| Perspective Therapeutics Inc | 7.452M |
| Electromed Inc | 0.167M |
| Xtant Medical Holdings Inc | 0.527M |
| Asensus Surgical Inc | 8.091M |